Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade)

Abbott Laboratories surged 14% after strong Q2 earnings and raised FY2026 guidance—see valuation, growth drivers and hold call. Click for this ABT stock update now.

Summary - Abbott Laboratories delivered strong Q2 results, beating expectations and raising FY 2026 guidance, prompting a 14% stock surge. - ABT’s valuation now appears fair, with normalized EPS estimated at $5.80 and an 18x P/E suggesting near-term value around $105. - Key segments like diagnostics and electrophysiology posted robust growth, while shareholder returns totaled $2.1 billion in Q2.

- I’m upgrading ABT to Hold; technicals are mixed, but profitability, yield, and pipeline progress support a neutral stance post-earnings. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.

I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results.

No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Our analysts are third party